171 related articles for article (PubMed ID: 28498022)
1. Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future.
Delitala AP; Delitala G; Sioni P; Fanciulli G
Curr Med Res Opin; 2017 Nov; 33(11):1985-1993. PubMed ID: 28498022
[TBL] [Abstract][Full Text] [Related]
2. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia.
Ladenson PW; Kristensen JD; Ridgway EC; Olsson AG; Carlsson B; Klein I; Baxter JD; Angelin B
N Engl J Med; 2010 Mar; 362(10):906-16. PubMed ID: 20220185
[TBL] [Abstract][Full Text] [Related]
3. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders.
Saponaro F; Sestito S; Runfola M; Rapposelli S; Chiellini G
Front Med (Lausanne); 2020; 7():331. PubMed ID: 32733906
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.
Elbers LP; Kastelein JJ; Sjouke B
Curr Atheroscler Rep; 2016 Mar; 18(3):14. PubMed ID: 26886134
[TBL] [Abstract][Full Text] [Related]
5. Sobetirome: a selective thyromimetic for the treatment of dyslipidemia.
Tancevski I; Demetz E; Eller P
Recent Pat Cardiovasc Drug Discov; 2011 Jan; 6(1):16-9. PubMed ID: 21208155
[TBL] [Abstract][Full Text] [Related]
6. Thyromimetics: a journey from bench to bed-side.
Tancevski I; Rudling M; Eller P
Pharmacol Ther; 2011 Jul; 131(1):33-9. PubMed ID: 21504761
[TBL] [Abstract][Full Text] [Related]
7. Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease.
Zhao M; Xie H; Shan H; Zheng Z; Li G; Li M; Hong L
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163026
[TBL] [Abstract][Full Text] [Related]
8. The resurgence of thyromimetics as lipid-modifying agents.
Tancevski I; Eller P; Patsch JR; Ritsch A
Curr Opin Investig Drugs; 2009 Sep; 10(9):912-8. PubMed ID: 19705333
[TBL] [Abstract][Full Text] [Related]
9. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
10. Sobetirome: the past, present and questions about the future.
Lammel Lindemann J; Webb P
Expert Opin Ther Targets; 2016; 20(2):145-9. PubMed ID: 26565124
[TBL] [Abstract][Full Text] [Related]
11. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans.
Berkenstam A; Kristensen J; Mellström K; Carlsson B; Malm J; Rehnmark S; Garg N; Andersson CM; Rudling M; Sjöberg F; Angelin B; Baxter JD
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):663-7. PubMed ID: 18160532
[TBL] [Abstract][Full Text] [Related]
12. Lipid lowering with thyroid hormone and thyromimetics.
Angelin B; Rudling M
Curr Opin Lipidol; 2010 Dec; 21(6):499-506. PubMed ID: 20935564
[TBL] [Abstract][Full Text] [Related]
13. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
Cariou B; Staels B
Expert Opin Investig Drugs; 2014 Oct; 23(10):1441-8. PubMed ID: 25164277
[TBL] [Abstract][Full Text] [Related]
14. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
16. An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-α mediated apolipoprotein A-I, A-II and C-III.
Liu C; Guo Q; Lu M; Li Y
Eur J Pharmacol; 2015 Aug; 761():362-74. PubMed ID: 25979856
[TBL] [Abstract][Full Text] [Related]
17. Thyroid hormone analogues: where do we stand in 2013?
Meruvu S; Ayers SD; Winnier G; Webb P
Thyroid; 2013 Nov; 23(11):1333-44. PubMed ID: 23915136
[TBL] [Abstract][Full Text] [Related]
18. Combination lipid therapy in type 2 diabetes mellitus.
Vergès B
Expert Opin Pharmacother; 2011 Jun; 12(9):1393-403. PubMed ID: 21323502
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
